keyword
MENU ▼
Read by QxMD icon Read
search

Ozurdex

keyword
https://www.readbyqxmd.com/read/29452450/-cost-comparison-of-licensed-intravitreal-therapies-for-insufficiently-anti-vegf-responding-fovea-involving-diabetic-macular-edema-in-germany
#1
Aljoscha S Neubauer, Christos Haritoglou, Michael W Ulbig
BACKGROUND: In the treatment of center-involving diabetic macular edema, despite initial therapy with an anti-VEGF compound, an insufficient response may occur. Further therapy options include a switch of anti-VEGF products or to corticosteroid implants, such as Fluocinolone acetonide or Dexamethasone. OBJECTIVES: Firstly, to investigate systematically which evidence-based study data are available describing the efficacy of in-label treatments after primary anti-VEGF treatment, secondly, to investigate which costs go along for the healthcare provider...
February 16, 2018: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29403585/effects-of-dexamethasone-implant-on-multifocal-electroretinography-in-central-retinal-vein-occlusion
#2
Muhammed Nurullah Bulut, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut, Yusuf Özertürk
Purpose: To investigate the effect of Ozurdex (dexamethasone intravitreal implant) on multifocal electroretinography (mfERG) findings during the treatment of macular edema secondary to the central retinal vein occlusion (CRVO). Methods: Fifteen eyes of 15 patients who were treated with Ozurdex implant due to CRVO-related macular edema were included in this study. Best corrected visual acuity (BCVA), central macular thickness (CMT), and mfERG evaluations were performed for all patients before injection of Ozurdex...
January 2018: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29380183/intravitreal-dexamethasone-implant-with-retinal-photocoagulation-for-adult-onset-coats-disease
#3
Kshitiz Kumar, Pallavi Raj, Nisha Chandnani, Amar Agarwal
PURPOSE: To report a case of adult-onset Coats' disease with secondary retinal vasoproliferative tumor managed with dexamethasone intravitreal implant and retinal photocoagulation. METHODS: Case study. RESULTS: A 41-year-old female with counting finger vision was diagnosed with Coats' disease with secondary retinal vasoproliferative tumor in right eye. Fundus examination revealed exudative retinopathy involving posterior pole and a retinal tumor located in the inferotemporal quadrant...
January 29, 2018: International Ophthalmology
https://www.readbyqxmd.com/read/29376223/bevacizumab-versus-dexamethasone-implant-followed-by-bevacizumab-for-the-treatment-of-macula-edema-associated-with-branch-retinal-vein-occlusion
#4
Su Young Moon, Kwan Hyuk Cho, Se Joon Woo, Sung Pyo Park, Yong Kyu Kim
PURPOSE: To compare visual and anatomical outcomes of intravitreal injections of bevacizumab and dexamethasone implant (Ozurdex) treatment for macular edema associated with branch retinal vein occlusion (BRVO). METHODS: We retrospectively reviewed patients who underwent intravitreal bevacizumab administered monthly on a pro re nata (PRN) basis (26 eyes, IVB group) or an initial 700-μg dexamethasone implant followed by a bevacizumab PRN injection (20 eyes, IVD group) for treatment of macular edema associated with BRVO...
January 25, 2018: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/29352994/topical-drug-delivery-devices-a-review
#5
REVIEW
C J F Bertens, M Gijs, R M M A Nuijts, F J H M van den Biggelaar
For the treatment and prevention of ocular diseases, most patients are treated with conventional drug delivery formulations such as eye drops or ointments. However, eye drops and ointments suffer from low patient compliance and low effective drug concentration at the target site. Therefore, new medical devices are being explored to improve drug delivery to the eye. Over the years, various delivery devices have been developed including resorbable devices, oval- and ring-shaped devices, rod-shaped devices, punctum plugs, contact lenses and corneal shields...
January 15, 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29304271/blau-jabs-syndrome-in-a-tertiary-ophthalmologic-center
#6
Heloisa Nascimento, Jacqueline M Sousa, Délia González Fernández, Gustavo H A Salomão, Elcio H Sato, Cristina Muccioli, Rubens Belfort
In a prospective case series of patients with Blau-Jabs syndrome (BJS) conducted in the Ophthalmology Department/Federal University of Sao Paulo, seven patients with clinical and ophthalmologic manifestations of the disease and a positive genetic test result for the presence of a mutation in the CARD15/NOD2 gene were followed for a minimal period of 1 year. All patients had uveitis, five had nummular corneal subepithelial opacities, and four had multifocal choroiditis. Oral prednisolone was administered to all patients; inflammation was controlled in six patients with at least one immunosuppressive drug...
January 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29260111/corneal-graft-failure-due-to-migration-of-ozurdex%C3%A2-implant-into-the-anterior-chamber
#7
Haifa A Madi, Stephen J Morgan, Saurabh Ghosh
Purpose: We report a case of corneal endothelial graft failure secondary to dexamethasone intravitreal implant (Ozurdex™) migration into the anterior chamber (AC). Observations: A 53-year-old man with a history of bilateral idiopathic chronic uveitis, had a right anterior vitrectomy and AC intraocular lens (ACIOL) with a peripheral iridotomy. He received an intravitreal Ozurdex™ implant for right cystoid macular oedema (CMO). Three months later he developed pseudophakic bullous keratopathy and underwent a Descemet stripping automated endothelial keratoplasty (DSAEK), combined with IOL exchange (ACIOL explantation followed by scleral fixated posterior chamber IOL)...
December 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29207977/acute-zonal-occult-outer-retinopathy-azoor-a-case-report-of-vision-improvement-after-intravitreal-injection-of-ozurdex
#8
Yi Chun Kuo, Nancy Chen, Rong Kung Tsai
BACKGROUND: AZOOR was first described by Gass in 1993 as a syndrome with rapid loss of one or more extensive zones of the outer retinal segments. It is characterized by photopsia, minimal funduscopic changes, and electroretinographic abnormalities. The efficacy of systemic steroids in treating AZOOR has been previously described and advocated by the concept of autoimmune retinopathy. However, the use of intravitreal of sustained-released steroid had not been mentioned to date. CASE PRESENTATION: A 34-year-old man had sudden onset of central scotoma and photopsia in the left eye...
December 6, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/29192395/intracrystalline-ozurdex%C3%A2-therapeutic-effect-maintained-for-18%C3%A2-months
#9
Rodrigo Clemente-Tomás, Delia Hernández-Pérez, Paulina Neira-Ibáñez, Francisco Farías-Rozas, Raúl Torrecillas-Picazo, Vanesa Osorio-Alayo, Antonio M Duch-Samper
INTRODUCTION: Ozurdex® is a sterile, sustained-release implant of dexamethasone. The device dissolves within the vitreous body and releases dexamethasone. Here we present a clinical case that demonstrates the sustained therapeutic efficacy of Ozurdex® when accidentally injected into the crystalline lens. METHODS: Case report. RESULTS: Sixty-three-year-old male in which we decided to prescribe the intravitreal injection of a dexamethasone implant (Ozurdex®) in the left eye because of macular oedema after branch retinal vein occlusion...
November 30, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/29183563/a-systematic-review-and-economic-evaluation-of-adalimumab-and-dexamethasone-for-treating-non-infectious-intermediate-uveitis-posterior-uveitis-or-panuveitis-in-adults
#10
Hazel Squires, Edith Poku, Inigo Bermejo, Katy Cooper, John Stevens, Jean Hamilton, Ruth Wong, Alastair Denniston, Ian Pearce, Fahd Quhill
BACKGROUND: Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a heterogeneous group of inflammatory eye disorders. Management includes local and systemic corticosteroids, immunosuppressants and biological drugs. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of subcutaneous adalimumab (Humira®; AbbVie Ltd, Maidenhead, UK) and a dexamethasone intravitreal implant (Ozurdex®; Allergan Ltd, Marlow, UK) in adults with non-infectious intermediate uveitis, posterior uveitis or panuveitis...
November 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/29155696/safety-of-consecutive-same-day-bilateral-intravitreal-dexamethasone-implant-ozurdex
#11
Kapil G Kapoor, James B Colchao
PURPOSE: The objective of this study was to evaluate patient safety and tolerance of consecutive bilateral intravitreal dexamethasone (Ozurdex) injections during a single visit for the treatment of cystoid macular edema secondary to retinal vein occlusion, diabetic macular edema, or noninfectious posterior uveitis. METHODS: This was a retrospective single-center institutional review board-approved study from March 1, 2013, through August 1, 2016. All patients had a complete ophthalmologic examination and optical coherence tomography imaging...
November 16, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/29119239/safety-and-efficacy-of-dexamethasone-intravitreal-implant-for-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-chinese-patients-randomized-sham-controlled-multicenter-study
#12
Xiaoxin Li, Ningli Wang, Xiaoling Liang, Gezhi Xu, Xiao-Yan Li, Jenny Jiao, Jean Lou, Yehia Hashad
PURPOSE: The purpose of this study was to evaluate the safety and efficacy of dexamethasone intravitreal implant 0.7 mg (DEX) for treatment of macular edema associated with retinal vein occlusion (RVO). METHODS: This study was a six-month, randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial with a 2-month open-label study extension. Patients with branch or central RVO received DEX (n = 129) or sham procedure (n = 130) in the study eye at baseline; all patients who met re-treatment criteria received DEX at month 6...
November 8, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29109896/outcomes-of-intravitreal-dexamethasone-implant-in-the-treatment-of-recalcitrant-diabetic-macular-edema
#13
Dorukcan Akıncıoğlu, Murat Küçükevcilioğlu, Ali Hakan Durukan, Seçkin Aykaş, Önder Ayyıldız, Fazıl Cüneyt Erdurman
Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients with recalcitrant diabetic macular edema. Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasone implantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and incidence of ocular side effects...
October 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29108392/cauterization-of-ozurdex-wound-for-the-prevention-of-scleral-leakage-in-vitrectomized-eyes
#14
Claudio Furino, Nicola Recchimurzo, Francesco Boscia, Giovanni Alessio
PURPOSE: To study if cauterization of the scleroconjuctival wound secondary to intravitreal dexamethasone implant in vitrectomized eyes is effective to avoid scleral leakage and hypotony. METHODS: A total of 35 vitrectomized eyes of 35 consecutive patients with macular edema who underwent a single intravitreal dexamethasone implant injection in the operating room at the Eye Clinic of the University of Bari, Italy, from 2013 to 2017 were retrospectively reviewed...
October 31, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29099501/efficacy-and-timing-of-adjunctive-therapy-in-the-anti-vegf-treatment-regimen-for-macular-oedema-in-retinal-vein-occlusion-12-month-real-world-result
#15
P L Lip, P Cikatricis, A Sarmad, E M Damato, R Chavan, A Mitra, S Elsherbiny, Y Yang, B Mushtaq
PurposeVarious combination treatment regimens have been tried to improve the short-term efficacy of intravitreal monotherapy for the treatment of macular oedema (MO) secondary to retinal vein occlusion (RVO). Our study introduces the RandOL protocol (Ranibizumab and Ozurdex with Laser photocoagulation) of initial anti-VEGF therapy, controlling recurrent non-ischaemic MO with an intravitreal steroid and applying laser therapy to non-perfused retina. We describe our 12-month follow-up experience on timing for adjunctive therapy and real-world effectiveness and safety data...
November 3, 2017: Eye
https://www.readbyqxmd.com/read/29098101/a-new-side-effect-of-intravitreal-dexamethasone-implant-ozurdex%C3%A2
#16
Erdem Eris, Gurkan Erdogan, Irfan Perente, Gokhan Demir, Burcin Kepez Yildiz, Ebru Demet Aygit
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has not been reported in the literature before.
2017: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/29062594/new-drugs-and-new-posterior-delivery-methods-in-cme
#17
João Rafael de Oliveira Dias, Renata Portella Nunes, Raquel Goldhardt
PURPOSE: To discuss the characteristics, indications and adverse events (AEs) of sustained-release corticosteroid devices for the treatment of cystoid macular edema (CME). RECENT FINDINGS: Ozurdex® is approved for the treatment of diabetic macular edema (DME), retinal vein occlusion related-CME and noninfectious posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 months making repeated intravitreal injections necessary for recurrent CME...
June 2017: Current Ophthalmology Reports
https://www.readbyqxmd.com/read/29020496/clinical-outcomes-of-adjunctive-sustained-release-intravitreal-dexamethasone-implants-in-tuberculosis-associated-multifocal-serpigenoid-choroiditis
#18
Lubhani Jain, Krushna Gopal Panda, Soumyava Basu
PURPOSE: To analyze the safety and efficacy of sustained-release intravitreal dexamethasone implant (Ozurdex) in management of TB-associated multifocal serpiginoid choroiditis (MSC). METHODS: Retrospective review of TB-associated MSC patients, treated with anti-TB therapy (ATT) and adjunctive intravitreal Ozurdex. RESULTS: Nine eyes of six patients were included. Four patients required Ozurdex implant for progressive or new lesions following ATT and two for additional systemic contraindications to corticosteroids - hyperglycemia and uncontrolled hypertension, respectively...
October 11, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28973374/effects-of-intravitreal-dexamethasone-implants-on-retinal-oxygen-saturation-vessel-diameter-and-retrobulbar-blood-flow-velocity-in-me-secondary-to-rvo
#19
Katharina Eibenberger, Leopold Schmetterer, Sandra Rezar-Dreindl, Piotr Wozniak, Reinhard Told, Georgios Mylonas, Christoph Krall, Ursula Schmidt-Erfurth, Stefan Sacu
Purpose: To investigate the effects of intravitreal 0.7 mg dexamethasone implants (Ozurdex) on arterial and venous oxygen saturation, retinal vessel diameter, and retrobulbar blood flow velocity in patients with macular edema (ME) due to retinal vein occlusion (RVO). Methods: This prospective, nonrandomized clinical trial included 40 eyes of 40 patients with ME due to RVO. Measurements of arterial and venous oxygen saturation and retinal vessel diameters were performed using the Dynamic Vessel Analyzer...
October 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28949790/the-effect-of-age-and-initial-central-retinal-thickness-on-earlier-need-of-repeat-ozurdex-treatment-for-macular-edema-due-to-retinal-vein-occlusion-a-retrospective-case-series
#20
Chun-Ju Lin, Huan-Sheng Chen, Cheng-Wen Su, Peng-Tai Tien, Jane-Ming Lin, Wen-Lu Chen, Chung-Yuan Kuo, Chun-Ting Lai, Yi-Yu Tsai
PURPOSE: To evaluate the effects of dexamethasone intravitreal implant (Ozurdex) and identify risk factors for repeated treatment in patients with macula edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). METHODS: Patients followed up for at least 6 months were enrolled from 2013 to 2016. Dexamethasone intravitreal implant was given as the baseline treatment. For evaluation of dexamethasone intravitreal implant effects and complications, the demographics, medical history, best-corrected visual acuity (BCVA), intraocular pressure, and central retinal thickness (CRT) were recorded...
September 26, 2017: Journal of Ocular Pharmacology and Therapeutics
keyword
keyword
33543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"